Zelenirstat

DB15567InvestigationalSmall molecule

Zelenirstat (PCLX-001) is a first-in-kind N-Myristoyltransferase (NMT) inhibitor being developed by Pacylex Pharmaceuticals (https://pacylex.com). Current studies have shown that zelenirstat works differently than other known cancer drugs and has high...

Mechanism: Pharmacologically active on Glycylpeptide N-tetradecanoyltransferase 1 and Glycylpeptide N-tetradecanoyltransferase 2
Curator reviewed
Formula / weight: C₂₄H₃₀Cl₂N₆O₂S · 537.5 g/mol (avg)
Code names: CCI-002 · DDD-86481 · PCLX-001

Resolves to

Compound

UNII5HY8BYC3Q6CAS1215011-08-7ChEMBLCHEMBL3357685

Structure

InChIKeyWKTSLVQYGBHNRV-UHFFFAOYSA-NSMILESCC(C)CC1=NN(C)C(C)=C1NS(=O)(=O)C1=C(Cl)C=C(C=C1Cl)C1=CC=NC(=C1)N1CCNCC1

Targets

P30419NMT1O60551NMT2

What you can answer from here — as of September 19, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Zelenirstat, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account